LAVA Therapeutics NV (LVTX) Stock Price, Forecast & Analysis

NASDAQ:LVTX • NL0015000AG6

1.74 USD
-0.07 (-3.87%)
Last: Nov 20, 2025, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

LVTX Key Statistics, Chart & Performance

Key Statistics
Market Cap45.78M
Revenue(TTM)11.98M
Net Income(TTM)-49.19M
Shares26.31M
Float22.00M
52 Week High2
52 Week Low0.85
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.86
PEN/A
Fwd PEN/A
Earnings (Next)03-26
IPO2021-03-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
LVTX short term performance overview.The bars show the price performance of LVTX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

LVTX long term performance overview.The bars show the price performance of LVTX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60

The current stock price of LVTX is 1.74 USD. In the past month the price increased by 8.07%. In the past year, price increased by 8.75%.

LAVA Therapeutics NV / LVTX Daily stock chart

LVTX Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to LVTX. When comparing the yearly performance of all stocks, LVTX is one of the better performing stocks in the market, outperforming 75.73% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
LVTX Full Technical Analysis Report

LVTX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to LVTX. While LVTX seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
LVTX Full Fundamental Analysis Report

LVTX Financial Highlights

Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -0.86. The EPS increased by 16.5% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -69.12%
ROE -190.76%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%41.3%
Sales Q2Q%N/A
EPS 1Y (TTM)16.5%
Revenue 1Y (TTM)77.01%
LVTX financials

LVTX Forecast & Estimates

7 analysts have analysed LVTX and the average price target is 1.4 USD. This implies a price decrease of -19.69% is expected in the next year compared to the current price of 1.74.

For the next year, analysts expect an EPS growth of 7.87% and a revenue growth -100% for LVTX


Analysts
Analysts45.71
Price Target1.4 (-19.54%)
EPS Next Y7.87%
Revenue Next Year-100%
LVTX Analyst EstimatesLVTX Analyst Ratings

LVTX Ownership

Ownership
Inst Owners27.59%
Ins Owners0.73%
Short Float %N/A
Short RatioN/A
LVTX Ownership

LVTX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.94409.148B
AMGN AMGEN INC16.38198.801B
GILD GILEAD SCIENCES INC17.38192.281B
VRTX VERTEX PHARMACEUTICALS INC24.11124.696B
REGN REGENERON PHARMACEUTICALS17.2984.911B
ALNY ALNYLAM PHARMACEUTICALS INC46.9341.535B
INSM INSMED INC N/A31.724B
BIIB BIOGEN INC12.9228.841B
NTRA NATERA INC N/A28.695B
UTHR UNITED THERAPEUTICS CORP16.0720.396B

Related stock screener links

View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges

About LVTX

Company Profile

LVTX logo image LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Company Info

LAVA Therapeutics NV

Yalelaan 60

Utrecht UTRECHT NL

Employees: 34

LVTX Company Website

LVTX Investor Relations

Phone: 31630003035

LAVA Therapeutics NV / LVTX FAQ

What does LVTX do?

LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company is headquartered in Utrecht, Utrecht and currently employs 34 full-time employees. The company went IPO on 2021-03-25. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.


Can you provide the latest stock price for LAVA Therapeutics NV?

The current stock price of LVTX is 1.74 USD. The price decreased by -3.87% in the last trading session.


Does LAVA Therapeutics NV pay dividends?

LVTX does not pay a dividend.


How is the ChartMill rating for LAVA Therapeutics NV?

LVTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Where is LAVA Therapeutics NV (LVTX) stock traded?

LVTX stock is listed on the Nasdaq exchange.


Can you provide the sector and industry classification for LAVA Therapeutics NV?

LAVA Therapeutics NV (LVTX) operates in the Health Care sector and the Biotechnology industry.